secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001193125-25-157303
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno expects Q2 2025 VYKAT XR net revenue of $31-33M; cash at $293.8M
-----------------------------------------------------------------------

- Preliminary net revenue of VYKAT XR for Q2 2025: $31.0-$33.0 million.
- Cash, equivalents & marketable securities at June 30, 2025: ~$293.8 million.
- Received 646 patient start forms from ~295 unique prescribers since March 26, 2025 approval.
- Debt outstanding under Oxford Financing LLC loan: ~$50.0 million, unchanged.
- First revenue quarter for VYKAT XR; financial close and review ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525157303/0001193125-25-157303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525157303/d98442d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-157303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer